{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:22:11Z","timestamp":1778253731940,"version":"3.51.4"},"reference-count":183,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Urological cancers including those of the prostate, bladder, and kidney, are prevalent and often lethal malignancies besides other less common ones like testicular and penile cancers. Current treatments have major limitations like side effects, recurrence, resistance, high costs, and poor quality of life. Nanotechnology offers promising solutions through enhanced diagnostic accuracy, targeted drug delivery, controlled release, and multimodal imaging. This review reflects clinical challenges and nanomedical advances across major urological cancers. In prostate cancer, nanoparticles improve delineation and radiosensitization in radiation therapy, enable fluorescent guidance in surgery, and enhance chemotherapy penetration in metastatic disease. Nanoparticles also overcome bladder permeability barriers to increase the residence time of intravesical therapy and chemotherapy agents. In renal cancer, nanocarriers potentiate tyrosine kinase inhibitors and immunotherapy while gene vectors and zinc oxide nanoparticles demonstrate antiproliferative effects. Across modalities, urological applications of nanomedicine include polymeric, liposomal, and metal nanoparticles for targeted therapy, prodrug delivery, photodynamic therapy, and thermal ablation. Biosafety assessments reveal favorable profiles but clinical translation remains limited, necessitating further trials. In conclusion, nanotechnology holds significant potential for earlier detection, precise intervention, and tailored treatment of urological malignancies, warranting expanded research to transform patient outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2024.1438297","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T20:43:10Z","timestamp":1723754590000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers"],"prefix":"10.3389","volume":"14","author":[{"given":"Mohammad Reza","family":"Fattahi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoureh","family":"Dehghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somayyeh","family":"Paknahad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafa","family":"Rahiminia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Zareie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Hoseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahmineh Rajaee","family":"Oroomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Motedayyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Arefnezhad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.36255\/exon-publications-urologic-cancers","volume-title":"Urologic Cancers","author":"Barber","year":"2022"},{"key":"B2","article-title":"Tumors: urologic cancer","volume-title":"Encyclopedia of Gerontology and Population Aging","author":"Mourey","year":"2022"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1300741","DOI":"10.3389\/fruro.2023.1300741","article-title":"Recent advances in the treatment of upper urinary tract and bladder cancers","volume":"3","author":"Zapa\u0142a","year":"2013","journal-title":"Front Urol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-42623-5","volume-title":"Urologic oncology","author":"Merseburger","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00345-013-1158-4","article-title":"Challenging treatment decision-making in older urologic cancer patients","volume":"32","author":"Ploussard","year":"2014","journal-title":"World J Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01637-w","article-title":"Emerging photodynamic\/sonodynamic therapies for urological cancers: progress and challenges","volume":"20","author":"Hu","year":"2022","journal-title":"J\u00a0Nanobiotechnology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12094-023-03117-5","article-title":"Nanoparticles for cancer therapy: a review of influencing factors and evaluation methods for biosafety","volume":"25","author":"Li","year":"2023","journal-title":"Clin Trans Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for cancer therapy: current progress and challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res Lett"},{"key":"B11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors\u2014A systematic review","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"B13","article-title":"Low-risk prostate cancer","volume-title":"Perez & Brady\u2019s Principles and Practice of Radiation Oncology","author":"Perez","year":"2018"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0287-y","article-title":"Considering the role of radical prostatectomy in 21st century prostate cancer care","volume":"17","author":"Costello","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.105","article-title":"Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods","volume":"178","author":"Yossepowitch","year":"2007","journal-title":"J Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.08.015","article-title":"Surgical results and complications for open, laparoscopic, and robot-assisted radical prostatectomy: a reverse systematic review","volume":"44","author":"Moretti","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.76","article-title":"The evolution of brachytherapy for prostate cancer","volume":"14","author":"Zaorsky","year":"2017","journal-title":"Nat Rev Urol"},{"key":"B19","first-page":"784","article-title":"Cancer of the prostate","volume-title":"DeVita, Hellman and Rosenberg\u2019s Cancer Principles and Practice of Oncology","author":"Reichert","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.3390\/cancers13153715","article-title":"Lutetium-177 labelled PSMA targeted therapy in advanced prostate cancer: current status and future perspectives","volume":"13","author":"Seitzer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.1713","article-title":"Impact of pelvic radiation therapy for prostate cancer on global metabolic profiles and microbiota-driven gastrointestinal late side effects: A longitudinal observational study","volume":"111","author":"Ferreira","year":"2021","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-020-00386-4","article-title":"Neglected side effects to curative prostate cancer treatments","volume":"33","author":"Nols\u00f8e","year":"2021","journal-title":"Int J Impot Res"},{"key":"B23","article-title":"CCN guidelines treatment by cancer type","volume-title":"Prostate Cancer","year":"2023"},{"key":"B24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jare.2022.11.001","article-title":"Biomolecule-functionalized nanoformulations for prostate cancer theranostics","volume":"51","author":"Pranav","year":"2023","journal-title":"J Adv Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/jcm12041446","article-title":"Immunotherapy for prostate cancer: A current systematic review and patient centric perspectives","volume":"12","author":"Rehman","year":"2023","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/cancers12071752","article-title":"Immunotherapy in prostate cancer","volume":"12","author":"Fay","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1001\/jamaoncol.2021.5009","article-title":"Immunotherapy adverse effects","volume":"7","author":"Brown","year":"2021","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.3390\/cancers15184537","article-title":"Current status of radiolabeled monoclonal antibodies targeting PSMA for imaging and therapy","volume":"15","author":"Abusalem","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-05255-5","article-title":"Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review","volume":"28","author":"Edmunds","year":"2020","journal-title":"Supportive Care Cancer"},{"key":"B30","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl Androl Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00745","article-title":"Potential applications of nanotechnology in urological cancer","volume":"9","author":"He","year":"2018","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2015.01.066","article-title":"Nanomaterials for early detection of cancer biomarker with special emphasis on gold nanoparticles in immunoassays\/sensors","volume":"68","author":"Devi","year":"2015","journal-title":"Biosens Bioelectron"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b00940","article-title":"Prostate-specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer","volume":"12","author":"Mangadlao","year":"2018","journal-title":"ACS Nano"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.04.032","article-title":"Prostate cancer targeted X-ray fluorescence imaging via gold nanoparticles functionalized with prostate-specific membrane antigen (PSMA)","volume":"111","author":"Hara","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/end.2021.0266","article-title":"Novel automated three-dimensional surgical planning tool and magnetic resonance imaging\/ultrasound fusion technology to perform nanoparticle ablation and cryoablation of the prostate for focal therapy","volume":"36","author":"Jue","year":"2022","journal-title":"J Endourol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-023-03936-z","article-title":"A review on selenium and gold nanoparticles combined photodynamic and photothermal prostate cancer tumors ablation","author":"Omiyale","year":"2023","journal-title":"Discover Nano"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.07.018","article-title":"Membrane dual-targeting probes: A promising strategy for fluorescence-guided prostate cancer surgery and lymph node metastases detection","volume":"13","author":"Wu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7150\/ntno.50095","article-title":"Intraoperative assessment and postsurgical treatment of prostate cancer tumors using tumor-targeted nanoprobes","volume":"5","author":"Teh","year":"2021","journal-title":"Nanotheranostics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12645-017-0027-z","article-title":"An overview of current practice in external beam radiation oncology with consideration to potential benefits and challenges for nanotechnology","volume":"8","author":"King","year":"2017","journal-title":"Cancer Nanotechnol"},{"key":"B40","first-page":"211","article-title":"\"Treatment plan optimization: an elusive goal,\" in advances in medical physics. Medical Physics Publishing (2008)","author":"Yorke","year":""},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.76184","article-title":"Advanced radiation treatment planning of prostate cancer","volume-title":"Prostate Cancer","author":"Tas","year":"2018"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1867","article-title":"Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials","volume":"15","author":"DuRoss","year":"2023","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1039\/C9SC02290B","article-title":"Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles","volume":"10","author":"Luo","year":"2019","journal-title":"Chem Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"20614","DOI":"10.1038\/srep20614","article-title":"Theranostic nanoseeds for efficacious internal radiation therapy of unresectable solid tumors","volume":"6","author":"Moeendarbari","year":"2016","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201701394","article-title":"2D ultrathin MXene-based drug-delivery nanoplatform for synergistic photothermal ablation and chemotherapy of cancer","volume":"7","author":"Han","year":"2018","journal-title":"Adv Healthc Mater"},{"key":"B46","doi-asserted-by":"publisher","first-page":"113714","DOI":"10.1016\/j.biopha.2022.113714","article-title":"Current progress of nanomedicine for prostate cancer diagnosis and treatment","volume":"155","author":"Zhao","year":"2022","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT","article-title":"Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE\/DOPA\/CaP nanoparticles for the treatment of castration-resistant prostate cancer","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2014.9052","article-title":"The role of nanotechnology in prostate cancer theranostic applications","volume":"14","author":"Cherian","year":"2014","journal-title":"J Nanosci Nanotechnol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/biomedicines8080253","article-title":"Curcumin nanoparticles and their cytotoxicity in docetaxel-resistant castration-resistant prostate cancer cells","volume":"8","author":"Tanaudommongkon","year":"2020","journal-title":"Biomedicines"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12011-020-02255-z","article-title":"Silver nanoparticles synthesized using Carica papaya leaf extract (AgNPs-PLE) causes cell cycle arrest and apoptosis in human prostate (DU145) cancer cells","volume":"199","author":"Singh","year":"2021","journal-title":"Biol Trace Elem Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/02652048.2022.2135785","article-title":"Development, evaluation, pharmacokinetic and biodistribution estimation of resveratrol-loaded solid lipid nanoparticles for prostate cancer targeting","volume":"39","author":"Sharma","year":"2022","journal-title":"J Microencapsul"},{"key":"B52","doi-asserted-by":"publisher","first-page":"16797","DOI":"10.1038\/s41598-021-96224-8","article-title":"Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy","volume":"11","author":"Khoobchandani","year":"2021","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/ijms21030869","article-title":"Cationic polymer nanoparticles-mediated delivery of miR-124 impairs tumorigenicity of prostate cancer cells","volume":"21","author":"Conte","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.1c00852","article-title":"Sequential release of pooled siRNAs and paclitaxel by aptamer-functionalized shell\u2013core nanoparticles to overcome paclitaxel resistance of prostate cancer","volume":"13","author":"Guo","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00244","article-title":"Multifunctional lipid nanoparticles for protein kinase N3 shRNA delivery and prostate cancer therapy","volume":"19","author":"Wang","year":"2022","journal-title":"Mol Pharm"},{"key":"B56","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.pdpdt.2021.102693","article-title":"Polylactide nanoparticles encapsulating indocyanine green for photothermal therapy of prostate cancer cells","volume":"37","author":"Akkurt","year":"2022","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.09.031","article-title":"Light-responsive smart nanocarriers for wirelessly controlled photodynamic therapy for prostate cancers","volume":"171","author":"Sun","year":"2023","journal-title":"Acta Biomater"},{"key":"B58","doi-asserted-by":"publisher","first-page":"120431","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice","volume":"266","author":"Islam","year":"2021","journal-title":"Biomaterials"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2019.07.003","article-title":"DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen","volume":"96","author":"Cole","year":"2019","journal-title":"Acta Biomater"},{"key":"B60","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12645-023-00228-0","article-title":"Dual enhancement in the radiosensitivity of prostate cancer through nanoparticles and chemotherapeutics","volume":"14","author":"Jackson","year":"2023","journal-title":"Cancer Nanotechnol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"102042","DOI":"10.1016\/j.nano.2019.102042","article-title":"Multifaceted NIR-responsive polymer-peptide-enveloped drug-loaded copper sulfide nanoplatform for chemo-phototherapy against highly tumorigenic prostate cancer","volume":"21","author":"Poudel","year":"2019","journal-title":"Nanomedicine"},{"key":"B62","doi-asserted-by":"publisher","first-page":"120416","DOI":"10.1016\/j.ijpharm.2021.120416","article-title":"Bioconjugated solid lipid nanoparticles (SLNs) for targeted prostate cancer therapy","volume":"599","author":"Akanda","year":"2021","journal-title":"Int J Pharm"},{"key":"B63","doi-asserted-by":"publisher","first-page":"112078","DOI":"10.1016\/j.msec.2021.112078","article-title":"Development of genistein-loaded gold nanoparticles and their antitumor potential against prostate cancer cell lines","volume":"124","author":"Vodnik","year":"2021","journal-title":"Materials Sci Engineering: C"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.34172\/bi.2023.24252","article-title":"PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy","volume":"13","author":"Yousefnezhad","year":"2023","journal-title":"BioImpacts"},{"key":"B65","first-page":"1","article-title":"RGD-decorated nanoliposomes for combined delivery of arsenic trioxide and curcumin to prostate cancer cells","volume":"397","author":"Khosravani","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.129233","article-title":"Tumor-targeted delivery of SNHG15 siRNA using a ZIF-8 nanoplatform: Towards a more effective prostate cancer therapy","author":"Saeinasab","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.3390\/ijms23136887","article-title":"Oxidative damage to mitochondria enhanced by ionising radiation and gold nanoparticles in cancer cells","volume":"23","author":"Tabatabaie","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102205","article-title":"Quantifying radiosensitization of PSMA-targeted gold nanoparticles on prostate cancer cells at megavoltage radiation energies by Monte Carlo simulation and local effect model","volume":"14","author":"Schmidt","year":"2022","journal-title":"Pharmaceutics"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s10856-023-06749-9","article-title":"Tumor-microenvironment responsive nano-carrier system for therapy of prostate cancer","volume":"34","author":"Li","year":"2023","journal-title":"J Mater Sci Mater Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302422","article-title":"Dual-pronged attack: pH-driven membrane-anchored NIR dual-type nano-photosensitizer excites immunogenic pyroptosis and sequester immune checkpoint for enhanced prostate cancer photo-immunotherapy","volume":"10","author":"Wang","year":"2023","journal-title":"Advanced Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1021\/mp300505w","article-title":"Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy","volume":"10","author":"Shenoi","year":"2013","journal-title":"Mol Pharm"},{"key":"B72","doi-asserted-by":"publisher","first-page":"101532","DOI":"10.1016\/j.nantod.2022.101532","article-title":"Nanotechnological approaches in prostate cancer therapy: integration of engineering and biology","volume":"45","author":"Ashrafizadeh","year":"2022","journal-title":"Nano Today"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1800122","DOI":"10.1002\/adtp.201800122","article-title":"Polymer nanoplatforms at work in prostate cancer therapy","volume":"2","author":"He","year":"2019","journal-title":"Adv Ther (Weinh)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27330","article-title":"A review of the etiology and epidemiology of bladder cancer: all you need to know","author":"Halaseh","year":"2022","journal-title":"Cureus"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9566-7","article-title":"Intravesical treatments of bladder cancer: review","volume":"25","author":"Shen","year":"2008","journal-title":"Pharm Res"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"B80","article-title":"CCN guidelines treatment by cancer type","volume-title":"Bladder Cancer","year":"2023"},{"key":"B81","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","article-title":"Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita","volume":"78","author":"Teoh","year":"2020","journal-title":"Eur Urol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/pharmaceutics14091909","article-title":"Nano-formulation based intravesical drug delivery systems: An overview of versatile approaches to improve urinary bladder diseases","volume":"14","author":"Sarfraz","year":"2022","journal-title":"Pharmaceutics"},{"key":"B83","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.biopha.2022.114062","article-title":"Current advances in the application of nanomedicine in bladder cancer","volume":"157","author":"Zhang","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00977","article-title":"Nano-BCG: A promising delivery system for treatment of human bladder cancer","volume":"8","author":"Buss","year":"2017","journal-title":"Front Pharmacol"},{"key":"B85","article-title":"Cancer of the bladder, ureter, and renal pelvis","volume-title":"DeVita, Hellman and Rosenberg\u2019s Cancer Principles and Practice of Oncology","author":"Feldman","year":"2023"},{"key":"B86","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clgc.2018.09.023","article-title":"Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer","volume":"17","author":"Royce","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57080749","article-title":"Bladder cancer: Current challenges and future directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Medicina (Lithuania)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: Challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar","year":"2010","journal-title":"J Controlled Release"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2017.02.016","article-title":"Poly - (l) - glutamic acid drug delivery system for the intravesical therapy of bladder cancer using WGA as targeting moiety","volume":"115","author":"Apfelthaler","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"B95","first-page":"1","article-title":"Smart nanocarriers as therapeutic platforms for bladder cancer","volume":"15","author":"Tong","year":"2021","journal-title":"Nano Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.08.120","article-title":"Advances in intravesical drug delivery systems to treat bladder cancer","volume":"532","author":"Kolawole","year":"2017","journal-title":"Int J Pharmaceutics"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12645-016-0015-8","article-title":"Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles","volume":"7","author":"Sweeney","year":"2016","journal-title":"Cancer Nanotechnol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2016.07.026","article-title":"Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer","volume":"104","author":"Lin","year":"2016","journal-title":"Biomaterials"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.11.091","article-title":"Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy","volume":"185","author":"Lu","year":"2011","journal-title":"J Urol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2147\/IJN","article-title":"Improvement and enhancement of antibladder carcinoma cell effects of heteronemin by the nanosized hyaluronan aggregation","volume":"11","author":"Huang","year":"2016","journal-title":"Int J Nanomedicine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-020-01752-7","article-title":"Catechol-functionalized alginate nanoparticles as Mucoadhesive carriers for Intravesical chemotherapy","volume":"21","author":"Sahatsapan","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/nano10071351","article-title":"Development of folic acid-conjugated and methylene blue-adsorbed Au@ TNA nanoparticles for enhanced photodynamic therapy of bladder cancer cells","volume":"10","author":"Hsu","year":"2020","journal-title":"Nanomaterials"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1362","article-title":"Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00448","article-title":"Immunotherapy strategy targeting programmed cell death ligand 1 and CD73 with macrophage-derived mimetic nanovesicles to treat bladder cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Mol Pharm"},{"key":"B105","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/cancers14102413","article-title":"Gold glyconanoparticles combined with 91\u201399 peptide of the bacterial toxin, listeriolysin O, are efficient immunotherapies in experimental bladder tumors","volume":"14","author":"Ter\u00e1n-Navarro","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.949704","article-title":"Multicomponent siRNA\/miRNA-loaded modified mesoporous silica nanoparticles targeted bladder cancer for a highly effective combination therapy","volume":"10","author":"Shahidi","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"124957","DOI":"10.1016\/j.ijbiomac.2023.124957","article-title":"Mucoadhesive gellan gum-based and carboxymethyl cellulose-based hydrogels containing gemcitabine and papain for bladder cancer treatment","volume":"242","author":"de Lima","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"8606","DOI":"10.1038\/s41598-017-09116-1","article-title":"Synergistic immuno photothermal nanotherapy (SYMPHONY) for the treatment of unresectable and metastatic cancers","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b03217","article-title":"Surface-enhanced Raman scattering nanoparticles for multiplexed imaging of bladder cancer tissue permeability and molecular phenotype","volume":"12","author":"Davis","year":"2018","journal-title":"ACS Nano"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.7b00405","article-title":"Near-infrared guided thermal-responsive nanomedicine against orthotopic superficial bladder cancer","volume":"3","author":"Gao","year":"2017","journal-title":"ACS Biomater Sci Eng"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2147\/IJN","article-title":"Biodistribution of gold nanoparticles in BBN-induced muscle-invasive bladdercancer in mice","volume":"12","author":"Smilowitz","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2015.09.058","article-title":"Magneto-thermally responsive hydrogels for bladder cancer treatment: Therapeutic efficacy and in vivo biodistribution","volume":"136","author":"Jaiswal","year":"2015","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112696119","article-title":"Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer","volume":"119","author":"Kong","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2147\/IJN","article-title":"Photothermal exposure of polydopamine-coated branched Au\u2013Ag nanoparticles induces cell cycle arrest, apoptosis, and autophagy in human bladder cancer cells","volume":"13","author":"Zhao","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.1c01217","article-title":"Fe (III)-doped Polyaminopyrrole nanoparticle for imaging-guided Photothermal therapy of bladder cancer","volume":"8","author":"Liu","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2018.12.113","article-title":"Multifunctional nanoclusters of NaYF4: Yb3+, Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer","volume":"97","author":"Cho","year":"2019","journal-title":"Materials Sci Engineering: C"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.09.027","article-title":"A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette\u2013Gu\u00e9rin in the treatment of bladder cancer","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00919","article-title":"Application of BCG-CWS as a systemic adjuvant by using nanoparticulation technology","volume":"15","author":"Masuda","year":"2018","journal-title":"Mol Pharm"},{"key":"B119","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/pharmaceutics11120652","article-title":"Enhanced intracellular delivery of BCG cell wall skeleton into bladder cancer cells using liposomes functionalized with folic acid and Pep-1 peptide","volume":"11","author":"Yoon","year":"2019","journal-title":"Pharmaceutics"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2100043","DOI":"10.1002\/adtp.202100043","article-title":"Fluorinated chitosan mediated synthesis of copper selenide nanoparticles with enhanced penetration for second near-infrared photothermal therapy of bladder cancer","volume":"4","author":"Zhang","year":"2021","journal-title":"Adv Ther (Weinh)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2017.08.020","article-title":"808 nm light triggered black TiO2 nanoparticles for killing of bladder cancer cells","volume":"81","author":"Ni","year":"2017","journal-title":"Materials Sci Engineering: C"},{"key":"B122","doi-asserted-by":"publisher","first-page":"112089","DOI":"10.1016\/j.msec.2021.112089","article-title":"Chitosan and chitosan\/PEG nanoparticles loaded with indole-3-carbinol: Characterization, computational study and potential effect on human bladder cancer cells","volume":"124","author":"Melo","year":"2021","journal-title":"Materials Sci Engineering: C"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1021\/acsabm.8b00501","article-title":"Paclitaxel\/chitosan nanosupensions provide enhanced intravesical bladder cancer therapy with sustained and prolonged delivery of paclitaxel","volume":"1","author":"Liu","year":"2018","journal-title":"ACS Appl Bio Mater"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201500235","article-title":"Active targeting of sorafenib: preparation, characterization, and in vitro testing of drug-loaded magnetic solid lipid nanoparticles","volume":"4","author":"Grillone","year":"2015","journal-title":"Adv Healthc Mater"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2022.3310","article-title":"Resveratrol nanoparticles suppresses migration and invasion of renal cell carcinoma cells by inhibiting matrix metalloproteinase 2 expression and extracellular signal-regulated kinase pathway","volume":"18","author":"Zhu","year":"2022","journal-title":"J BioMed Nanotechnol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13590","article-title":"Nanotechnology combined therapy: tyrosine kinase-bound gold nanorod and laser thermal ablation produce a synergistic higher treatment response of renal cell carcinoma in a murine model","volume":"119","author":"Liu","year":"2017","journal-title":"BJU Int"},{"key":"B127","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.02.034","article-title":"Polymeric nanoparticles encapsulating novel TLR7\/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy","volume":"164","author":"Kim","year":"2018","journal-title":"Biomaterials"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.08.053","article-title":"Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages","volume":"183","author":"Alsaab","year":"2018","journal-title":"Biomaterials"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0832","article-title":"Combining DNA vaccine and AIM2 in H1 nanoparticles exert anti-renal carcinoma effects via enhancing tumor-specific multi-functional CD8+ T-cell responses","volume":"18","author":"Chai","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.13652","article-title":"Sertraline\/ICG-loaded liposome for dual-modality imaging and effective chemo-photothermal combination therapy against metastatic clear cell renal cell carcinoma","volume":"95","author":"Lei","year":"2020","journal-title":"Chem Biol Drug Des"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-020-03033-y","article-title":"Laser enhancement of cancer cell destruction by photothermal therapy conjugated glutathione (GSH)-coated small-sized gold nanoparticles","volume":"36","author":"Al-Barram","year":"2021","journal-title":"Lasers Med Sci"},{"key":"B132","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.mtbio.2022.100513","article-title":"3D-CEUS tracking of injectable chemo-sonodynamic therapy-enabled mop-up of residual renal cell carcinoma after thermal ablation","volume":"18","author":"Li","year":"2023","journal-title":"Mater Today Bio"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.01.027","article-title":"Focused ultrasound-triggered release of tyrosine kinase inhibitor from thermosensitive liposomes for treatment of renal cell carcinoma","volume":"106","author":"Abshire","year":"2017","journal-title":"J Pharm Sci"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.02.086","article-title":"Involvement of Caveolin-1-mediated transcytosis in the intratumoral accumulation of liposomes","volume":"525","author":"Sakurai","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1348-z","article-title":"Peglated-H1\/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma","volume":"38","author":"Gao","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.biomaterials.2017.09.008","article-title":"Cuprous oxide nanoparticles trigger ER stress-induced apoptosis by regulating copper trafficking and overcoming resistance to sunitinib therapy in renal cancer","volume":"146","author":"Yang","year":"2017","journal-title":"Biomaterials"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0746-y","article-title":"Economic burden of renal cell carcinoma\u2014Part I: an updated review","volume":"37","author":"Chien","year":"2019","journal-title":"PharmacoEconomics"},{"key":"B138","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume-title":"The Lancet","author":"Capitanio","year":"2016"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.04.100","article-title":"Renal mass and localized renal cancer: AUA guideline","volume":"198","author":"Campbell","year":"2017","journal-title":"J Urol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.08.028","article-title":"Surgical metastasectomy in renal cell carcinoma: a systematic review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.3390\/cancers15133455","article-title":"Beyond the knife in renal cell carcinoma: A systematic review\u2014To ablate or not to ablate","volume":"15","author":"Green","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B144","article-title":"CCN guidelines treatment by cancer type","volume-title":"Kidney Cancer","year":"2023"},{"key":"B145","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/JU.0000000000000591","article-title":"Impact of resection technique on perioperative outcomes and surgical margins after partial nephrectomy for localized renal masses: A prospective multicenter study","volume":"203","author":"Minervini","year":"2020","journal-title":"J Urology"},{"key":"B146","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/02656736.2019.1647352","article-title":"Percutaneous ablation techniques for renal cell carcinoma: current status and future trends","volume":"36","author":"Filippiadis","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"B147","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00345-014-1284-7","article-title":"The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation","volume":"32","author":"Klatte","year":"2014","journal-title":"World J Urol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiotherapy Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.08.010","article-title":"Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature","volume":"131","author":"Francolini","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.08.007","article-title":"Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma","volume":"19","author":"Wilson","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14059338","article-title":"Biomarkers for anti-angiogenic therapy in cancer","volume":"14","author":"Wehland","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B152","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/ijms18020461","article-title":"Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Randrup Hansen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.09.056","article-title":"Exosomal microRNA-1 and MYO15A as a target for therapy and diagnosis in renal cell carcinoma","volume":"630","author":"Yoshino","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B154","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12964-022-00996-z","article-title":"UBE2O ubiquitinates PTRF\/CAVIN1 and inhibits the secretion of exosome-related PTRF\/CAVIN1","volume":"20","author":"Cen","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13842","article-title":"H1\/pAIM2 nanoparticles exert anti-tumour effects that is associated with the inflammasome activation in renal carcinoma","volume":"22","author":"Chai","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"2883404","DOI":"10.1155\/2022\/2883404","article-title":"Zinc oxide nanoparticle inhibits tumorigenesis of renal cell carcinoma by modulating lipid metabolism targeting miR-454-3p to repressing metabolism enzyme ACSL4","volume":"2022","author":"Zhou","year":"2022","journal-title":"J Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"102370","DOI":"10.1016\/j.nano.2021.102370","article-title":"Photothermal therapy enhance the anti-mitochondrial metabolism effect of lonidamine to renal cell carcinoma in homologous-targeted nanosystem","volume":"34","author":"Chen","year":"2021","journal-title":"Nanomedicine"},{"key":"B158","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12032-020-1346-1","article-title":"Extracellular vesicle isolation from human renal cancer tissue","volume":"37","author":"Zieren","year":"2020","journal-title":"Med Oncol"},{"key":"B159","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1038\/s41598-019-45629-7","article-title":"Detection of circulating tumor cells in blood by shell-isolated nanoparticle - enhanced Raman spectroscopy (SHINERS) in microfluidic device","volume":"9","author":"Nici\u0144ski","year":"2019","journal-title":"Sci Rep"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098404","article-title":"Clinical validation of a size-based microfluidic device for circulating tumor cell isolation and analysis in renal cell carcinoma","volume":"24","author":"Leit\u00e3o","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B161","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13046-022-02467-2","article-title":"Transfection with Plasmid-Encoding lncRNA-SLERCC nanoparticle-mediated delivery suppressed tumor progression in renal cell carcinoma","volume":"41","author":"Mao","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","author":"Siegel","year":"2020","journal-title":"Cancer J Clin"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.004","article-title":"Global trends in testicular cancer incidence and mortality","volume":"60","author":"Rosen","year":"2011","journal-title":"Eur Urol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2006.08.029","article-title":"Incidence trends in primary Malignant penile cancer","volume":"25","author":"Barnholtz-Sloan","year":"2007","journal-title":"Urologic Oncology: Semin Original Investigations"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-9-8","article-title":"Identifying the needs of penile cancer sufferers: A systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer","volume":"9","author":"Maddineni","year":"2009","journal-title":"BMC Urol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.2147\/OTT","article-title":"Optimal management of upper tract urothelial carcinoma: Current perspectives","volume":"13","author":"Leow","year":"2020","journal-title":"OncoTargets Ther"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6931","article-title":"Health-related quality of life in long-term survivors of testicular cancer","volume":"27","author":"Rossen","year":"2009","journal-title":"J Clin Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.21037\/tau","article-title":"Psychosocial impact of penile carcinoma","volume":"6","author":"Audenet","year":"2017","journal-title":"Trans Andrology Urol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1021\/ja057254a","article-title":"Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods","volume":"128","author":"Huang","year":"2006","journal-title":"J Am Chem Soc"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.664123","article-title":"Improvement of gold nanorods in photothermal therapy: recent progress and perspective","volume":"12","author":"Liao","year":"2021","journal-title":"Front Pharmacol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-008-0288-6","article-title":"Non-invasive and minimally invasive staging of regional lymph nodes in penile cancer","volume":"27","author":"Hughes","year":"2009","journal-title":"World J Urol"},{"key":"B172","first-page":"65","article-title":"The potential of nanoparticle-enhanced imaging","volume-title":"Urologic Oncology: Seminars and Original Investigations","author":"Feldman","year":"2008"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/27\/42\/425103","article-title":"Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer","volume":"27","author":"Pan","year":"2016","journal-title":"Nanotechnology"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1039\/C9BM01377F","article-title":"Targeted multifunctional nanomaterials with MRI, chemotherapy and photothermal therapy for the diagnosis and treatment of bladder cancer","volume":"8","author":"Tao","year":"2020","journal-title":"Biomater Sci"},{"key":"B175","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-37287-2_12","article-title":"Recent status of the current clinical trials going on for superparamagnetic materials","volume-title":"Superparamagnetic Materials for Cancer Medicine","author":"Chikhaliwala","year":"2023"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2023-0080","article-title":"Efficacy and safety of nano-paclitaxel formulation for cancer treatment: evidence from randomized clinical trials","author":"Deng","year":"2023","journal-title":"Future Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng Transl Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat Commun"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3109\/02652048.2013.879932","article-title":"Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells","volume":"31","author":"Wolfram","year":"2014","journal-title":"J Microencapsul"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2012.05.013","article-title":"The big picture on nanomedicine: The state of investigational and approved nanomedicine products","volume":"9","author":"Etheridge","year":"2013","journal-title":"Nanomedicine: Nanotechnology Biology Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-040210-162544","article-title":"Nanoparticle delivery of cancer drugs","volume":"63","author":"Wang","year":"2012","journal-title":"Annu Rev Med"}],"updated-by":[{"DOI":"10.3389\/fonc.2024.1516456","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1438297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:10:03Z","timestamp":1730797803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1438297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":183,"alternative-id":["10.3389\/fonc.2024.1438297"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1438297","relation":{"erratum":[{"id-type":"doi","id":"10.3389\/fonc.2024.1516456","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"article-number":"1438297"}}